R
R. C. Coombes
Researcher at Imperial College London
Publications - 5
Citations - 1016
R. C. Coombes is an academic researcher from Imperial College London. The author has contributed to research in topics: Breast cancer & Hazard ratio. The author has an hindex of 5, co-authored 5 publications receiving 977 citations.
Papers
More filters
Journal ArticleDOI
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes,Lucy Kilburn,Claire Snowdon,Robert Paridaens,Robert E. Coleman,Stephen E. Jones,Jacek Jassem,Cjh van de Velde,Thierry Delozier,Isabel Alvarez,L. Del Mastro,Olaf Ortmann,K Diedrich,Alan S. Coates,Emilio Bajetta,Stig Holmberg,D. Dodwell,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,John F. Forbes,Monica Castiglione,N Stuart,Alan L Stewart,Lesley Fallowfield,Gianfilippo Bertelli,Emma Hall,R. G. Bogle,M. Carpentieri,E Colajori,M Subar,E. Ireland,Judith M Bliss +33 more
TL;DR: The results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.
Journal ArticleDOI
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
Donato Nitti,Jaques Wils,J. Guimarães dos Santos,G. Fountzilas,Pierfranco Conte,C. Sava,A. Tres,R. C. Coombes,D. Crivellari,Alberto Marchet,Eduardo Sánchez,Judith M Bliss,J. Homewood,M.L. Couvreur,Emma Hall,Benoit Baron,E. Woods,M. Emson,E. Van Cutsem,Mario Lise +19 more
TL;DR: Neither FAMTX nor FEMTX can be advocated as adjuvant treatment in patients who undergo resection for gastric cancer.
Journal ArticleDOI
High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.
R. C. Coombes,Anthony Howell,M. Emson,Clare Peckitt,C Gallagher,C Bengala,A. Tres,Richard Welch,P Lawton,Robert D. Rubens,E. Woods,Joanne S Haviland,D Vigushin,E Kanfer,Judith M Bliss +14 more
TL;DR: No benefit has been observed from replacing three cycles of conventional chemotherapy with the HDT regimen described here, and patients should continue to receive conventional chemotherapy as adjuvant therapy for breast cancer.
Journal ArticleDOI
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy
J.-C. Gazet,H. T. Ford,Richard Gray,C. McConkey,R. Sutcliffe,J. Quilliam,V. Makinde,S. Lowndes,R. C. Coombes +8 more
TL;DR: In this study neoadjuvant treatment with endocrine or chemotherapy provided no obvious survival benefit to women with breast cancer, but it does allow avoidance of surgery in some cases.
Journal ArticleDOI
Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer
H. T. Ford,R. C. Coombes,J.-C. Gazet,Richard Gray,C. McConkey,R. Sutcliffe,J. Quilliam,S. Lowndes +7 more
TL;DR: Post-operative radiotherapy produced a clear-cut reduction in locoregional recurrence, but did not influence the incidence of distant metastases or time of death, which is dependent on the intensity of post-treatment follow-up and investigation.